AGEN
Price
$4.16
Change
-$0.02 (-0.48%)
Updated
Sep 2 closing price
Capitalization
132.55M
NBY
Price
$2.28
Change
+$0.50 (+28.09%)
Updated
Sep 2 closing price
Capitalization
13.28M
Interact to see
Advertisement

AGEN vs NBY

Header iconAGEN vs NBY Comparison
Open Charts AGEN vs NBYBanner chart's image
Agenus
Price$4.16
Change-$0.02 (-0.48%)
Volume$402.52K
Capitalization132.55M
NovaBay Pharmaceuticals
Price$2.28
Change+$0.50 (+28.09%)
Volume$6.59M
Capitalization13.28M
AGEN vs NBY Comparison Chart in %
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. NBY commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Buy and NBY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (AGEN: $4.16 vs. NBY: $2.28)
Brand notoriety: AGEN and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 45% vs. NBY: 78%
Market capitalization -- AGEN: $132.55M vs. NBY: $13.28M
AGEN [@Biotechnology] is valued at $132.55M. NBY’s [@Biotechnology] market capitalization is $13.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $102.81B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 1 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • AGEN’s FA Score: 1 green, 4 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 5 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 5 bearish.
  • NBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NBY is a better buy in the short-term than AGEN.

Price Growth

AGEN (@Biotechnology) experienced а -10.15% price change this week, while NBY (@Biotechnology) price change was +153.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.48%. For the same industry, the average monthly price growth was +24.35%, and the average quarterly price growth was +32.72%.

Industries' Descriptions

@Biotechnology (+0.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGEN($133M) has a higher market cap than NBY($13.3M). NBY has higher P/E ratio than AGEN: NBY (0.99) vs AGEN (0.14). NBY YTD gains are higher at: 196.173 vs. AGEN (52.555). NBY has higher annual earnings (EBITDA): -7.05M vs. AGEN (-74.93M). AGEN has more cash in the bank: 9.53M vs. NBY (5.34M). NBY has less debt than AGEN: NBY (1.04M) vs AGEN (90.5M). AGEN has higher revenues than NBY: AGEN (102M) vs NBY (9.78M).
AGENNBYAGEN / NBY
Capitalization133M13.3M1,000%
EBITDA-74.93M-7.05M1,063%
Gain YTD52.555196.17327%
P/E Ratio0.140.9915%
Revenue102M9.78M1,043%
Total Cash9.53M5.34M178%
Total Debt90.5M1.04M8,685%
FUNDAMENTALS RATINGS
AGEN vs NBY: Fundamental Ratings
AGEN
NBY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
5934
P/E GROWTH RATING
1..100
251
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (29) in the Biotechnology industry is significantly better than the same rating for AGEN (96). This means that NBY’s stock grew significantly faster than AGEN’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that NBY’s stock grew similarly to AGEN’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for AGEN (100). This means that NBY’s stock grew significantly faster than AGEN’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is in the same range as AGEN (59). This means that NBY’s stock grew similarly to AGEN’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is in the same range as AGEN (25). This means that NBY’s stock grew similarly to AGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENNBY
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
85%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 5 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
84%
Advances
ODDS (%)
Bullish Trend 19 days ago
84%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
82%
Bearish Trend 5 days ago
84%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REPYY16.460.05
+0.30%
Repsol S.A.
SPSAF221.00N/A
N/A
SOPRA SA
ACAT0.05N/A
N/A
Acasia Technology, Inc.
HMRFF0.66-0.01
-1.21%
HOMERUN RES INC
EUBG0.27-0.06
-17.43%
ENTREPRENEUR UNIVERSE BRIGHT GROUP

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been closely correlated with NCNA. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
-1.65%
NCNA - AGEN
92%
Closely correlated
-0.31%
NBY - AGEN
90%
Closely correlated
+7.88%
TAOX - AGEN
90%
Closely correlated
-11.08%
ALLR - AGEN
88%
Closely correlated
+2.67%
JAGX - AGEN
87%
Closely correlated
+1.87%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+7.88%
CDTX - NBY
93%
Closely correlated
+0.25%
NCNA - NBY
93%
Closely correlated
-0.31%
TAOX - NBY
91%
Closely correlated
-11.08%
RNAC - NBY
91%
Closely correlated
-2.24%
AGEN - NBY
90%
Closely correlated
-1.65%
More